Short Interest in Daré Bioscience, Inc. (NASDAQ:DARE) Decreases By 13.3%

Daré Bioscience, Inc. (NASDAQ:DARE) was the recipient of a large decline in short interest in the month of November. As of November 15th, there was short interest totalling 25,500 shares, a decline of 13.3% from the October 31st total of 29,400 shares. Based on an average daily volume of 41,600 shares, the short-interest ratio is presently 0.6 days. Currently, 0.3% of the shares of the company are short sold.

Analyst Ratings Changes

A number of research firms have issued reports on DARE. Maxim Group reissued a “hold” rating on shares of Daré Bioscience in a report on Wednesday, August 14th. HC Wainwright reissued a “buy” rating and issued a $12.00 price objective on shares of Daré Bioscience in a report on Friday, November 15th.

Daré Bioscience Stock Performance

NASDAQ DARE traded down $0.02 during trading on Tuesday, reaching $3.28. The company’s stock had a trading volume of 43,729 shares, compared to its average volume of 46,856. The firm has a 50 day moving average price of $3.55 and a 200 day moving average price of $3.87. Daré Bioscience has a 12 month low of $3.05 and a 12 month high of $7.56.

Institutional Trading of Daré Bioscience

A hedge fund recently raised its stake in Daré Bioscience stock. Renaissance Technologies LLC lifted its position in shares of Daré Bioscience, Inc. (NASDAQ:DARE) by 2.1% in the second quarter, according to the company in its most recent 13F filing with the Securities and Exchange Commission. The firm owned 778,700 shares of the biotechnology company’s stock after acquiring an additional 15,800 shares during the period. Renaissance Technologies LLC owned approximately 9.25% of Daré Bioscience worth $262,000 as of its most recent filing with the Securities and Exchange Commission. 6.70% of the stock is currently owned by institutional investors and hedge funds.

About Daré Bioscience

Daré Bioscience, Inc, a biopharmaceutical company, identifies, develops, and markets products for women's health in the United States. It develops therapies in the areas of contraception, reproductive health, menopause, fertility, and sexual and vaginal health. The company offers XACIATO for the treatment of bacterial vaginosis in female patients 12 years of age and older.